Puberty Blocker Trial Paused: Regulator Recused Over Bias Concerns

Concerns over potential bias have led to Professor Jacob George being removed from involvement in the Pathways clinical trial, a study examining the utilize of puberty blockers in young people questioning their gender identity. The move follows the emergence of social media posts from last year in which Professor George expressed gender-critical views, including describing author J.K. Rowling as a “treasure of our time.” The trial, which had been paused in February, aims to assess the effects of puberty blockers, but its future is now subject to further review.

Pathways Trial: A Pause for Scrutiny

Professor George, appointed chief medical and scientific officer at the Medicines and Healthcare products Regulatory Agency (MHRA) in January, initially raised concerns that prompted the government to pause the Pathways trial. The trial was designed to recruit approximately 226 young people over three years to evaluate the impact of puberty blockers. The initial plan included participants as young as 10 or 11, depending on biological sex, though researchers anticipated that the rigorous selection process would likely result in an older cohort. However, the MHRA subsequently indicated a minimum age of 14 due to “unquantified risk” of “long-term biological harms.”

The decision to recuse Professor George was announced by the MHRA on Saturday, framing it as a precautionary measure. An MHRA spokesperson stated the agency’s top priority remains the safety and wellbeing of trial participants, and that complex clinical trials are continuously reviewed with active scientific dialogue with trial sponsors. The agency emphasized its multidisciplinary team of experts will continue working with King’s College London to determine the next steps.

Context: The Cass Review and Evolving Guidance

The Pathways trial was initiated following recommendations from the Cass review, an independent review of gender identity services for children and young people in England. The Cass review, led by Dr. Hilary Cass, concluded in April 2024 that the evidence base supporting the benefits of puberty blockers for young people with gender dysphoria was “poor.” The review’s findings highlighted a demand for more robust research in this area.

Dr. Cass has consistently stated that while the evidence was weak, a trial was necessary to better understand the effects of puberty blockers, given the strong beliefs held by clinicians, families, and young people regarding their potential benefits. The trial aimed to provide that evidence, but the pause and now Professor George’s recusal introduce further complexity.

Concerns Over Impartiality

The controversy surrounding Professor George’s involvement centers on his publicly expressed views on gender identity. Beyond his praise for J.K. Rowling, he also voiced concerns about the “denial of basic biological fact” in relation to the eligibility of Olympic boxer Imane Khelif to compete as a woman. The Guardian reported on Khelif’s case, which involved questions about her testosterone levels and eligibility for competition.

Dr. Max Davie, a consultant paediatrician with experience at the NHS Children and Young People’s Gender Service, argued that Professor George’s personal views created a conflict of interest. He stated that while Professor George is entitled to his opinions, they should not influence his public duties. Davie believes the MHRA’s decision to halt the trial was not scientifically justified and suggests Professor George’s views were a primary driver.

Understanding Puberty Blockers and Gender Dysphoria

Puberty blockers are medications that temporarily suppress the physical changes of puberty, such as breast development or facial hair growth. They are sometimes used for young people experiencing gender dysphoria – distress caused by a mismatch between their gender identity and their sex assigned at birth – to allow them time to explore their gender identity before undergoing irreversible changes. It’s important to note that puberty blockers are not a cure for gender dysphoria, and their long-term effects are still being studied.

The use of puberty blockers is a complex and sensitive issue, with differing opinions among medical professionals and advocacy groups. Some argue they can significantly improve the wellbeing of young people with gender dysphoria, while others express concerns about potential side effects and the lack of long-term data. The Pathways trial was intended to address some of these uncertainties.

What Comes Next: A Trial in Limbo

The future of the Pathways trial remains uncertain. The MHRA has committed to working with King’s College London to determine the next steps, but the recusal of Professor George and the concerns raised about the trial’s methodology and age criteria will likely require significant deliberation. The agency’s statement emphasizes a commitment to evidence-based decision-making, but the process will undoubtedly be influenced by the ongoing debate surrounding gender identity and the appropriate care for young people experiencing gender dysphoria. Further updates are expected as the MHRA and King’s College London assess the situation and consider potential modifications to the trial protocol. The MHRA’s official statement provides the most current information available.